Browsing Other ICR Research by author "Bliss, Judith"
Now showing items 1-2 of 2
-
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, H; Sipos, O; Parker, JS; Hoadley, KA; Quist, J; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-15)PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation ... -
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, CE; Garber, JE; Gelber, RD; Yothers, G; Taboada, M; et al. (ELSEVIER, 2022-10-10)BACKGROUND: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or ...